| scholarly article | Q13442814 |
| P356 | DOI | 10.2337/DIACARE.20.9.1353 |
| P698 | PubMed publication ID | 9283777 |
| P50 | author | Benjamin Glaser | Q55719492 |
| P2093 | author name string | E Cerasi | |
| H Ilkova | |||
| A Tunçkale | |||
| N Bagriaçik | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 1353-1356 | |
| P577 | publication date | 1997-09-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment | |
| P478 | volume | 20 |
| Q39413477 | 5'-AMP-activated protein kinase plays an essential role in geniposide-regulated glucose-stimulated insulin secretion in rat pancreatic INS-1 β cells |
| Q35060164 | A practical scheme for the initial out-patient management of type-2 diabetes mellitus |
| Q43959182 | A rapid increase in beta-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment |
| Q35043882 | Aqueous fraction of Beta vulgaris ameliorates hyperglycemia in diabetic mice due to enhanced glucose stimulated insulin secretion, mediated by acetylcholine and GLP-1, and elevated glucose uptake via increased membrane bound GLUT4 transporters |
| Q35879135 | Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment |
| Q33979688 | Basal insulin requirements on continuous subcutaneous insulin infusion during the first 12 months after diagnosis of type 1 diabetes mellitus |
| Q36798634 | Beta cells in type 2 diabetes - a crucial contribution to pathogenesis |
| Q36453667 | Blood Glucose Fluctuations in Type 2 Diabetes Patients Treated with Multiple Daily Injections |
| Q38503820 | Case Study: Remission of Type 2 Diabetes After Outpatient Basal Insulin Therapy |
| Q38115799 | Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes |
| Q35305506 | Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes |
| Q38116766 | Complementing insulin therapy to achieve glycemic control |
| Q33403231 | Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy |
| Q37796152 | Continuous subcutaneous insulin infusion (CSII) using an external insulin pump for the treatment of type 2 diabetes |
| Q38095652 | Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes |
| Q73428567 | Diabetes Prevention in high-risk women with gestational diabetes |
| Q35767312 | Diabetes in African Americans: unique pathophysiologic features |
| Q43959179 | Does insulin preserve beta-cell function in type 2 diabetes? |
| Q35853273 | Early basal insulin therapy decreases new-onset diabetes after renal transplantation. |
| Q37624279 | Early insulin treatment in type 2 diabetes: what are the pros? |
| Q37577178 | Early insulinization to prevent diabetes progression |
| Q34163305 | Early intensive insulin treatment for induction of long-term glycaemic control in type 2 diabetes. |
| Q85305515 | Early therapy for type 2 diabetes in China |
| Q51276351 | Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes. |
| Q40187492 | Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial |
| Q46576386 | Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. |
| Q42477142 | Effect of short‐term intensive insulin therapy on quality of life in type 2 diabetes |
| Q36310386 | Effects of Liraglutide Combined with Short-Term Continuous Subcutaneous Insulin Infusion on Glycemic Control and Beta Cell Function in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A Pilot Study |
| Q42493971 | Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes |
| Q31144148 | Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data |
| Q34594675 | Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes |
| Q37384190 | Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial. |
| Q51367108 | Effects of the modified linggui zhugan decoction (see text) combined with short-term very low calorie diets on glycemic control in newly diagnosed type 2 diabetics. |
| Q34381281 | Emerging treatment options for type 2 diabetes |
| Q37639310 | Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial |
| Q64884015 | Fasting Plasma Glucose Indicates Reversibility of the Acute Insulin Response after Short-Term Intensive Insulin Therapy in Patients with Various Duration of Type 2 Diabetes. |
| Q35065639 | Glucotoxicity and beta-cell failure in type 2 diabetes mellitus |
| Q42140404 | Improvement in insulin sensitivity following intensive insulin therapy and association of glucagon with long-term diabetes remission |
| Q73373575 | Improvement in severe insulin resistance with frequent injections of lispro insulin |
| Q44598061 | Improvement of β-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control |
| Q37794288 | In support of an early polypharmacy approach to the treatment of type 2 diabetes |
| Q36194286 | Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy |
| Q44389355 | Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy |
| Q36856384 | Inhaled human [rDNA origin] insulin, a novel formulation for diabetes mellitus |
| Q38065105 | Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia |
| Q42477903 | Initial short‐term intensive insulin therapy as a strategy for evaluating the preservation of beta‐cell function with oral antidiabetic medications: a pilot study with sitagliptin |
| Q88871989 | Insulin dependent and independent normalization of blood glucose levels reduces the enhanced rewarding effects of nicotine in a rodent model of diabetes |
| Q30311226 | Insulin pump therapy for type 2 diabetes |
| Q35219417 | Insulin therapy for type 2 diabetes |
| Q73531395 | Insulin therapy in type 2 diabetes |
| Q37364945 | Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? |
| Q53475411 | Intensive insulin therapy in newly diagnosed type 2 diabetes. |
| Q36975546 | Intensive intravenous infusion of insulin in diabetic cats |
| Q34586302 | Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial |
| Q26830871 | Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes |
| Q58717025 | Male Patients with Longstanding Type 2 Diabetes Have a Higher Incidence of Hypoglycemia Compared with Female Patients |
| Q34862358 | Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes |
| Q24642503 | Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes |
| Q37653764 | Metabolic Stress and Compromised Identity of Pancreatic Beta Cells. |
| Q55447873 | Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes. |
| Q31895027 | Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function |
| Q42918366 | No need for the needle (at first). |
| Q35645893 | Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment |
| Q35221336 | Novel views on new-onset diabetes after transplantation: development, prevention and treatment. |
| Q34087245 | Optimising therapy for insulin-treated type 2 diabetes mellitus |
| Q36920511 | Overcoming barriers to glycemic control in African Americans with type-2 diabetes: benefits of insulin therapy |
| Q41054906 | Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy |
| Q50475837 | Pancreatic β-Cells Express the Fetal Islet Hormone Gastrin in Rodent and Human Diabetes. |
| Q38951177 | Pancreatic β-cell identity in diabetes. |
| Q89475403 | Practical application of short-term intensive insulin therapy based on the concept of "treat to target" to reduce hypoglycaemia in routine clinical site |
| Q37804597 | Preservation of Beta-Cell Function in Type 2 Diabetes |
| Q35944769 | Preventing and treating obesity in girls and young women to curb the epidemic |
| Q33980529 | Pro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation |
| Q46495626 | Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist-managed anticoagulation service |
| Q55288083 | Rethinking the Viability and Utility of Inhaled Insulin in Clinical Practice. |
| Q61463649 | Reviewing the evidence: Feline diabetic remission |
| Q58710567 | Short Course of Insulin Treatment versus Metformin in Newly Diagnosed Patients with Type 2 Diabetes |
| Q37192464 | Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus |
| Q38038662 | Short-term intensified insulin treatment in type 2 diabetes: long-term effects on β-cell function |
| Q38246691 | Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps |
| Q42511731 | Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9. |
| Q38259937 | Systematic review of feline diabetic remission: separating fact from opinion |
| Q37782506 | Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus |
| Q34102119 | The Effect of Early Insulin Therapy on Pancreatic β-Cell Function and Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients |
| Q51346853 | The Effect of Early Intensive Insulin Therapy on Body Fat Distribution and β-Cell Function in Newly Diagnosed Type 2 Diabetes. |
| Q38442291 | The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study. |
| Q84355336 | The influence of insulin pump treatment on metabolic syndrome parameters in type 2 diabetes mellitus |
| Q38836724 | The role of insulin pump therapy for type 2 diabetes mellitus |
| Q61795976 | Understanding the manifestation of diabetes in sub Saharan Africa to inform therapeutic approaches and preventive strategies: a narrative review |
| Q34219402 | We can change the natural history of type 2 diabetes |
| Q47099550 | Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients. |
| Q83656419 | [Management of type 2 diabetes: from guidelines to clinical practice] |
| Q36947018 | beta-cell function and anti-diabetic pharmacotherapy |
| Q33588325 | β-Cell failure in type 2 diabetes |
| Q36047178 | β-cell function preservation after 3.5 years of intensive diabetes therapy |
Search more.